Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 1/20 | 0.31 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.31 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL991129 | 1.00 | SLC6A2 (0.31) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL31203719 | 0.77 | SLC6A2 (0.33) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL11026469 | 0.77 | SLC6A2 (0.33) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL11913741 | 0.77 | SLC6A2 (0.33) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL15731786 | 0.76 | SLC6A2 (0.32) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL11298343 | 0.76 | SLC6A2 (0.32) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL11025847 | 0.74 | TSHR (0.31) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL11027378 | 0.74 | TSHR (0.31) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL15835723 | 0.74 | SLC6A2 (0.32) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL11302632 | 0.72 | APLNR (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2665732-B1 | FUSED AMINODIHYDROTHIAZINE DERIVATIVES USEFUL AS BACE INHIBITORS | EISAI R&D MAN CO LTD (JP) | 2016-03-30 | — | — | EP | disclosed |
| US-9139594-B2 | Fused aminodihydropyrimidone derivatives | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2015-09-22 | — | — | US | disclosed |
| US-9139594-B2 | Fused aminodihydropyrimidone derivatives | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2015-09-22 | — | — | US | disclosed |
| US-9079914-B2 | Fused aminodihydro-oxazine derivatives | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2015-07-14 | — | — | US | disclosed |
| US-9079914-B2 | Fused aminodihydro-oxazine derivatives | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2015-07-14 | — | — | US | disclosed |
| US-8940734-B2 | Fused aminodihydrothiazine derivatives | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2015-01-27 | — | — | US | disclosed |
| US-8940734-B2 | Fused aminodihydrothiazine derivatives | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2015-01-27 | — | — | US | disclosed |
| US-8940734-B2 | Fused aminodihydrothiazine derivatives | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2015-01-27 | — | — | US | disclosed |
| US-20140142091-A1 | FUSED AMINODIHYDROTHIAZINE DERIVATIVES | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2014-05-22 | — | — | US | disclosed |
| US-20140142091-A1 | FUSED AMINODIHYDROTHIAZINE DERIVATIVES | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2014-05-22 | — | — | US | disclosed |
| WO-2012098213-A1 | FUSED AMINODIHYDROTHIAZINE DERIVATIVES USEFUL AS BACE INHIBITORS | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2012-07-26 | — | — | WO | disclosed |
| US-20120190672-A1 | FUSED AMINODIHYDROTHIAZINE DERIVATIVES | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2012-07-26 | — | — | US | disclosed |
| US-20120190672-A1 | FUSED AMINODIHYDROTHIAZINE DERIVATIVES | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2012-07-26 | — | — | US | disclosed |
| WO-2012098213-A1 | FUSED AMINODIHYDROTHIAZINE DERIVATIVES USEFUL AS BACE INHIBITORS | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2012-07-26 | — | — | WO | disclosed |
| US-20120190672-A1 | FUSED AMINODIHYDROTHIAZINE DERIVATIVES | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2012-07-26 | — | — | US | disclosed |
| EP-2456771-A1 | FUSED AMINODIHYDROPYRIMIDONE DERIVATIVES | Eisai R&D Management Co., Ltd. (JP) | 2012-05-30 | — | — | EP | disclosed |
| EP-2456774-A1 | FUSED AMINODIHYDRO-OXAZINE DERIVATIVES | Eisai R&D Management Co., Ltd. (JP) | 2012-05-30 | — | — | EP | disclosed |
| WO-2011009897-A1 | FUSED AMINODIHYDROPYRIMIDONE DERIVATIVES | EISAI R&D MANAGEMENT CO., LTD (JP) | 2011-01-27 | — | — | WO | disclosed |
| WO-2011009898-A1 | FUSED AMINODIHYDRO-OXAZINE DERIVATIVES | EISAI R&D MANAGEMENT CO., LTD (JP) | 2011-01-27 | — | — | WO | disclosed |
| WO-2011009898-A1 | FUSED AMINODIHYDRO-OXAZINE DERIVATIVES | EISAI R&D MANAGEMENT CO., LTD (JP) | 2011-01-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120190672-A1 | FUSED AMINODIHYDROTHIAZINE DERIVATIVES | BACE1, APP, BACE2 | SLC6A2 886/4885SLC6A4 1946/4885SLC6A3 852/4885 |
| US-20140142091-A1 | FUSED AMINODIHYDROTHIAZINE DERIVATIVES | BACE1, APP, BACE2 | SLC6A2 886/4885SLC6A4 1946/4885SLC6A3 852/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.